Work

First-line treatment of metastatic NSCLC (mNSCLC) patients without actionable mutations in U.S. community oncology clinical practice.

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.7_suppl.307

Authors: Caroline McKay, Ashwini Arunachalam, Thomas A. Burke, Xiting Cao, Amy P Abernethy, David Paul Carbone

Institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), Rutgers, The State University of New Jersey, Flatiron Health (United States), The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2590811781

Cites:

Cited by:

Related to: 10